Selecta Biosciences Inc (NASDAQ:SELB) Expands Potential for ImmTOR Platform As Well As Its Streamlined Structure
The clinical-stage biotechnology company, Selecta Biosciences Inc (NASDAQ:SELB) under the...
Read More
Regenxbio Inc (NASDAQ:RGNX) Sees a Continued Progress Across Programs; With Promising Results on RGX-314 for The Wet Age-Related Macular Degeneration
Not all companies are lucky when giving their end-year reports, but for Regenxbio Inc...
Read More
Inhibrx Developing CAR T Cell Immunotherapies In Collaboration With bluebird bio Inc (NASDAQ:BLUE)
Durham-based gene therapy company, bluebird bio Inc (NASDAQ:BLUE) has collaborated with Inhibrx...
Read More
Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) Lunches Phase 1B/2 Clinical Trial of Rebastinib Combined with Carboplatin in Solid Tumors
Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) has launched a phase 1b/2 study of Rebastinib combined...
Read More
Positive Top-Line Data From Phase 2 Study For CSU Is A Good Sign For Allakos Inc. (NASDAQ:ALLK)
In November last year, Allakos Inc. (NASDAQ:ALLK) initiated Phase 2 study for Xolair-naïve chronic...
Read More
Athenex, Inc. (NASDAQ:ATNX) Seeks To Take Control Of KX2-391 Supply Chain With Creation Of A New Factory In China
Athenex, Inc. (NASDAQ:ATNX) is slowing evolving from a purely discovering and development drug...
Read More
Denali Therapeutics Inc. (NASDAQ:DNLI) Makes Advances In Development Of DNL747 Which Is In Phase 1
Denali Therapeutics Inc. (NASDAQ:DNLI) is working hard to push its product candidates in the...
Read More
Jaguar Health Inc. (NASDAQ:JAGX) Reports Robust Figures In Sales For 4Q2018 Even As It Fails To Provide Guidance For 2019
Jaguar Health Inc. (NASDAQ:JAGX) reported the financial figures from Q4 2018 and the performance...
Read More
Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) Will Reveal Top-Line Data For Phase 3 REGENERATE In Q1 2019
This year is pivotal for Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) as two studies under its...
Read More
IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) Set To Leverage Its DEL License And Expertise To Venture In CBD-Based Pharmaceutical Products
IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) is part of the premier pharmaceutical...
Read More
Radius Health Inc (NASDAQ:RDUS) Surpasses Its 2018 Financial Guidance of $95 To $98 Million
Radius Health Inc (NASDAQ:RDUS) announced about a week ago that it managed to surpass its guidance...
Read More
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Announces Positive Open-Label- Extension Results Of The Second Phase OASIS Trial Of Etrasimod In Treatment Of Ulcerative Colitis
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) has released positive open-label extension data for the...
Read More
Recent Articles
